CR6620A - Amino acidos biciclicos como agentes farmaceuticos - Google Patents
Amino acidos biciclicos como agentes farmaceuticosInfo
- Publication number
- CR6620A CR6620A CR6620A CR6620A CR6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bicycle
- acids
- amino
- pharmaceutical agents
- diseases
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000003483 hypokinetic effect Effects 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
Abstract
Se trata de compuestos de aminoacidos biciclicos utiles en el tratamiento de la epilepsia, lagunas mentales, hipoquinesia, enfermedades craneales, neurodegenerativas, depresion, ansiedad, panico, dolor, artritis, enfermedades neuropatologicas y desordenes del sueno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16072599P | 1999-10-20 | 1999-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR6620A true CR6620A (es) | 2004-02-02 |
Family
ID=22578159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR6620A CR6620A (es) | 1999-10-20 | 2002-04-18 | Amino acidos biciclicos como agentes farmaceuticos |
Country Status (50)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| MXPA02010668A (es) * | 2000-06-26 | 2003-03-10 | Warner Lambert Co | Analogos de gabapentina para alteraciones del sueno. |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| EP1226820A1 (en) * | 2001-01-26 | 2002-07-31 | Warner-Lambert Company | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| EA006396B1 (ru) | 2001-04-19 | 2005-12-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си | Конденсированные бициклические аминокислоты |
| GB2375108A (en) * | 2001-05-04 | 2002-11-06 | Warner Lambert Co | Production of a bicycloheptanone |
| GB2375109A (en) * | 2001-05-04 | 2002-11-06 | Warner Lambert Co | Process for preparing bicyclic amino acid |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| WO2002100347A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| KR20040081478A (ko) | 2002-01-31 | 2004-09-21 | 워너-램버트 캄파니 엘엘씨 | 이명을 치료하기 위한 알파 2 델타 리간드 |
| IL162932A0 (en) * | 2002-02-22 | 2005-11-20 | Warner Lambert Co | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| AU2003239752A1 (en) * | 2002-06-27 | 2004-01-19 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| CA2494811A1 (en) * | 2002-08-15 | 2004-02-26 | Pfizer Inc. | Therapeutic use of fused bicyclic or tricyclic amino acids |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| GB0223072D0 (en) | 2002-10-04 | 2002-11-13 | Pfizer Ltd | Cyclic nitromethyl acetic acid derivatives |
| US7018818B2 (en) | 2002-10-04 | 2006-03-28 | Pfizer Inc. | Intermediates in the preparation of therapeutic fused bicyclic amino acids |
| AU2003297927A1 (en) | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050085636A (ko) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체 |
| MXPA06002789A (es) | 2003-09-12 | 2006-06-14 | Pfizer | Combinaciones que comprenden ligandos alfa-2-delta. |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
| UA94979C2 (uk) | 2006-12-22 | 2011-06-25 | Рекордати Айеленд Лимитед | КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП |
| BR122013020635A2 (pt) | 2007-09-28 | 2019-08-06 | Daiichi Sankyo Company, Limited | Composto |
| CA2756750C (en) | 2009-03-26 | 2014-05-13 | Daiichi Sankyo Company, Limited | A method for producing bicyclic .gamma.-amino acid derivative |
| CN103582622B (zh) | 2011-06-08 | 2015-06-10 | 第一三共株式会社 | 经由亚胺鎓盐制备双环化合物的方法 |
| KR101816337B1 (ko) | 2011-06-08 | 2018-01-08 | 다이이찌 산쿄 가부시키가이샤 | 클라이젠 전위 반응에 의한 2 고리성 화합물의 제조 방법 |
| IN2014MN01046A (es) | 2011-12-15 | 2015-05-01 | Daiichi Sankyo Companyltd | |
| EP2837689B1 (en) | 2012-04-10 | 2017-02-15 | Daiichi Sankyo Company, Limited | Optical resolution method for bicyclic compound using enzyme |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| TWI635071B (zh) | 2013-07-08 | 2018-09-11 | 第一三共股份有限公司 | 光學活性二環γ－胺基酸衍生物及其製造方法 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN113045410A (zh) * | 2021-03-29 | 2021-06-29 | 华东理工大学 | 一种双环降二萜类化合物及其合成基因及制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641129A (en) | 1969-06-17 | 1972-02-08 | Merck & Co Inc | Antifibrinolytic compounds |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE69834204T2 (de) | 1997-10-27 | 2007-03-29 | Warner-Lambert Co. Llc | Zyklische aminosäuren und deren derivate als arzneimittel |
-
2000
- 2000-10-05 HN HN2000000224A patent/HN2000000224A/es unknown
- 2000-10-06 SV SV2000000188A patent/SV2001000188A/es not_active Application Discontinuation
- 2000-10-17 CZ CZ20021310A patent/CZ295960B6/cs not_active IP Right Cessation
- 2000-10-17 UA UA2002032434A patent/UA72931C2/uk unknown
- 2000-10-17 TR TR2002/01094T patent/TR200201094T2/xx unknown
- 2000-10-17 IL IL16406000A patent/IL164060A0/xx unknown
- 2000-10-17 BR BRPI0014972-1A patent/BR0014972B1/pt not_active IP Right Cessation
- 2000-10-17 AP AP2004003186A patent/AP2004003186A0/xx unknown
- 2000-10-17 DZ DZ003197A patent/DZ3197A1/xx active
- 2000-10-17 WO PCT/US2000/028687 patent/WO2001028978A1/en not_active Ceased
- 2000-10-17 CN CNB008145644A patent/CN1165518C/zh not_active Expired - Fee Related
- 2000-10-17 EP EP04027485A patent/EP1506955B1/en not_active Expired - Lifetime
- 2000-10-17 YU YU73004A patent/YU73004A/sh unknown
- 2000-10-17 PL PL00354607A patent/PL354607A1/xx not_active Application Discontinuation
- 2000-10-17 HR HR20020428A patent/HRP20020428B1/xx not_active IP Right Cessation
- 2000-10-17 AT AT00972226T patent/ATE293590T1/de not_active IP Right Cessation
- 2000-10-17 MX MXPA02003229A patent/MXPA02003229A/es active IP Right Grant
- 2000-10-17 AP APAP/P/2002/002517A patent/AP2002002517A0/en unknown
- 2000-10-17 ES ES04027485T patent/ES2282785T3/es not_active Expired - Lifetime
- 2000-10-17 SI SI200030670T patent/SI1226110T1/xx unknown
- 2000-10-17 HR HRP20040709 patent/HRP20040709A2/xx not_active Application Discontinuation
- 2000-10-17 JP JP2001531783A patent/JP3632191B2/ja not_active Expired - Fee Related
- 2000-10-17 IL IL14914300A patent/IL149143A0/xx not_active IP Right Cessation
- 2000-10-17 DE DE60019628T patent/DE60019628T2/de not_active Expired - Lifetime
- 2000-10-17 KR KR1020067002249A patent/KR100566462B1/ko not_active Expired - Fee Related
- 2000-10-17 EA EA200200293A patent/EA005206B1/ru unknown
- 2000-10-17 SK SK523-2002A patent/SK5232002A3/sk unknown
- 2000-10-17 KR KR1020027005036A patent/KR100593349B1/ko not_active Expired - Fee Related
- 2000-10-17 HK HK03101868.4A patent/HK1049826B/zh not_active IP Right Cessation
- 2000-10-17 AT AT04027485T patent/ATE358116T1/de not_active IP Right Cessation
- 2000-10-17 AU AU10920/01A patent/AU778871B2/en not_active Ceased
- 2000-10-17 EP EP00972226A patent/EP1226110B1/en not_active Expired - Lifetime
- 2000-10-17 YU YU29302A patent/YU29302A/sh unknown
- 2000-10-17 ES ES00972226T patent/ES2237464T3/es not_active Expired - Lifetime
- 2000-10-17 EE EEP200200211A patent/EE200200211A/xx unknown
- 2000-10-17 OA OA1200200117A patent/OA12070A/en unknown
- 2000-10-17 US US10/130,023 patent/US6689906B1/en not_active Expired - Fee Related
- 2000-10-17 GE GE4783A patent/GEP20043297B/en unknown
- 2000-10-17 DE DE60034157T patent/DE60034157T2/de not_active Expired - Lifetime
- 2000-10-17 TR TR2005/00221T patent/TR200500221T2/xx unknown
- 2000-10-17 PT PT00972226T patent/PT1226110E/pt unknown
- 2000-10-17 NZ NZ517961A patent/NZ517961A/xx unknown
- 2000-10-17 CA CA2386297A patent/CA2386297C/en not_active Expired - Fee Related
- 2000-10-17 HU HU0203325A patent/HUP0203325A3/hu unknown
- 2000-10-18 MY MYPI20004896A patent/MY127678A/en unknown
- 2000-10-18 PA PA20008505201A patent/PA8505201A1/es unknown
- 2000-10-19 DO DO2000000083A patent/DOP2000000083A/es unknown
- 2000-10-19 CO CO00079741A patent/CO5280060A1/es not_active Application Discontinuation
- 2000-10-19 GT GT200000183AK patent/GT200000183AA/es unknown
- 2000-10-19 GT GT200000183A patent/GT200000183A/es unknown
- 2000-10-19 AR ARP000105497A patent/AR026087A1/es unknown
- 2000-10-19 PE PE2000001116A patent/PE20010740A1/es not_active Application Discontinuation
- 2000-10-20 TW TW089122115A patent/TWI225855B/zh not_active IP Right Cessation
- 2000-10-20 TW TW093125953A patent/TW200505824A/zh unknown
-
2002
- 2002-03-28 ZA ZA200202543A patent/ZA200202543B/xx unknown
- 2002-04-15 IL IL149143A patent/IL149143A/en unknown
- 2002-04-16 NO NO20021780A patent/NO20021780D0/no not_active Application Discontinuation
- 2002-04-16 CU CU78A patent/CU23112A3/es unknown
- 2002-04-17 IS IS6348A patent/IS6348A/is unknown
- 2002-04-18 CR CR6620A patent/CR6620A/es not_active Application Discontinuation
- 2002-05-10 MA MA26634A patent/MA26842A1/fr unknown
- 2002-05-20 BG BG108860A patent/BG108860A/en unknown
- 2002-05-20 BG BG106719A patent/BG106719A/bg unknown
-
2004
- 2004-01-21 US US10/762,026 patent/US6835751B2/en not_active Expired - Fee Related
- 2004-07-28 EC EC2004005393A patent/ECSP045393A/es unknown
- 2004-08-17 AR ARP040102937A patent/AR045456A2/es unknown
- 2004-09-01 NO NO20043663A patent/NO20043663L/no not_active Application Discontinuation
- 2004-09-14 JP JP2004266488A patent/JP3744928B2/ja not_active Expired - Fee Related
- 2004-10-08 IS IS7497A patent/IS7497A/is unknown
-
2005
- 2005-03-23 AU AU2005201268A patent/AU2005201268A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR6620A (es) | Amino acidos biciclicos como agentes farmaceuticos | |
| BR9712651A (pt) | cidos gama-aminobutìricos substituìdos com agentes farmacêuticos. | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| ATE552837T1 (de) | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| MXPA05008649A (es) | Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios. | |
| HRP20041179B1 (hr) | Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti | |
| ES2185591T3 (es) | Amino hererociclos utiles como agentes farmaceuticos. | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| IL163951A0 (en) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| PE20051156A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| DE60008293D1 (de) | Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung | |
| PT1235573E (pt) | Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais | |
| ATE302000T1 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
| HRP20030953A2 (en) | PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | |
| DE602006009848D1 (de) | Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung | |
| BRPI0417797A (pt) | soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos | |
| EA200500538A1 (ru) | Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы | |
| HRP20040104A2 (en) | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | |
| Lioubimov et al. | P. 5.043 Changes in lymphocytes functionalactivity as an indication of the epileptic preconvulsive status | |
| BR9812265A (pt) | Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias. | |
| HK1098671A (en) | Use of 1-oxadibenzo e,h azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | |
| HK1098669A (en) | Use of 1-thia-dibenzo e,h azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | |
| AR031525A1 (es) | Uso de una composicion que comprende un compuesto de modafinil para el tratamiento de la enfermedad de hiperactividad con déficit de atencion y la fatiga de esclerosis multiple, composiciones farmaceuticas, un envase terapeutico, metodo de identificacion de un compuesto que modula selectivamente la |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |